A Study of Toripalimab or Combining With Temozolomide（iv） in the Treatment of Advanced/Metastatic Malignant Melanoma
This study evaluate toripalimab or combining with temozolomide for injection in the treatment of advanced/metastatic malignant melanoma. Participants in arm A receive toripalimab, in arm B receive toripalimab plus temozolomide
Malignant Melanoma
DRUG: toripalimab|DRUG: Temozolomide Injection
ORR, objective response rate, 8 weeks
OS, overall survival, 3 years|PFS, Progression free survival, 1 years|DCR, Disease contral rate, 8 weeks|1-year PFS, progression free survival at 1 year (1year PFS) rate, 1 year after treatment initiation|6-month PFS, progression free survival at 6 months (6-month PFS) rate, 6 months after treatment initiation|1-year OS, overall survival at 1 year (1 year OS) rate, 1 year after treatment initiation|2-year OS, overall survival at 2 years (2 year OS) rate, 2 year after treatment initiation
This study evaluate toripalimab or combining with temozolomide for injection in the treatment of advanced/metastatic malignant melanoma. Participants in arm A receive toripalimab, in arm B receive toripalimab plus temozolomide